Program
Tirzepatide
Also written as “Arm 5- Tirzepatide”, “Tirzepatide Dose 1” and “Tirzepatide Dose 2”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus, Type 1 · Psoriasis · Non-alcoholic Fatty Liver Disease, led by 4 companies.
Drug pageTirzepatide: every studyAll 192 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 6917 open or running | phase 4since Jun 22, 2022 | Apr 29, 2016 | Nov 2026phase 1 · NCT07299084 |
| Florida Academic Centers Research and Educationits history only | 11 open or running | no phasesince Mar 1, 2024 | Mar 1, 2024 | none ahead |
| Hudson Biotechits history only | 11 open or running | phase 3since Mar 8, 2026 | Mar 8, 2026 | Feb 14, 2027phase 3 · NCT07481747 |
| Lexaria Bioscience | 10 open or running | phase 1since Oct 16, 2024 | Oct 16, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lexaria Bioscience only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named tirzepatideINNProposed as its International Nonproprietary Name in WHO's List 119
- Oct 16, 2024First study: phase 1 study in Type2diabetesFirst studyNCT06648031 · 148 enrolled · Australia
TargetBeta
“Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| olatorepatide | Hansoh Pharmaceutical Group | phase 3 | 12 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
The one study Lexaria Bioscience leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06648031Type2diabetes · Australia | 1 | Completed | Jul 31, 2025 | 148 |
How it is read
Names in the registry
- “Tirzepatide”, 69 entries
- “Arm 5- Tirzepatide”, 1 entry
- “Tirzepatide Dose 1”, 1 entry
- “Tirzepatide Dose 2”, 1 entry
- “TIRZEPATIDE”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 29 studies
- Obesity, 21 studies
- Diabetes Mellitus, Type 1, 3 studies
- Psoriasis, 2 studies
- Non-alcoholic Fatty Liver Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.